Rifaximin and lactulose to prevent confusion after TIPS
Part of Brain & nervous system, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether taking rifaximin plus lactulose can prevent a brain problem called hepatic encephalopathy (confusion) after TIPS, a procedure to reduce pressure in the liver. It may help people who are having TIPS planned and are at risk of this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have confirmed liver scarring (cirrhosis) from biopsy, scan (like Fibroscan), or standard test results
- You are scheduled for an elective TIPS procedure for hard-to-control fluid buildup or repeat bleeding from enlarged veins (varices)
- You have risk factors such as not improving with water pills, kidney/electrolyte problems from water pills, or bleeding that endoscopic treatment and beta-blockers couldn’t control
- You have not taken rifaximin within the last 3 months and you are not using ciclosporin
- You should not have certain exclusions like planned emergency TIPS within 72 hours, non-cirrhotic portal pressure, portal vein blockage, HIV, major neurologic conditions, or be pregnant/breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a fecal microbiota transplant (FMT) – putting carefully screened donor bacteria into your colon – can help prevent repeated episodes of confusion and memory problems (hepatic encephalopathy) that can happen after a liver procedure called TIPS. The goal is to improve your thinking and quality of life by restoring healthy gut bacteria.
This trial tests if transferring healthy bacteria into your gut (fecal microbiota transplant) can help people who still get confusion episodes (hepatic encephalopathy) even after a TIPS procedure and while on standard medications like lactulose and rifaximin.
This trial compares two treatments—BCAA supplements and rifaximin—to see which is better at preventing another episode of confusion or coma in people with cirrhosis who have already had one. If you qualify, you would receive one of these treatments for several months.
This Phase 3 trial tests whether nitazoxanide can help stop hepatic encephalopathy (a “liver-to-brain” confusion problem) from coming back. It’s for adults with cirrhosis who have had at least one past episode, aiming to improve safety and prevent recurrence.
This study tests a procedure to narrow a stent in the liver to reduce episodes of confusion caused by toxins reaching the brain. It may help people who still have frequent confusion despite standard treatments.
This study tests a new way to guide a procedure called TIPS, which helps relieve pressure in the liver caused by fluid buildup or bleeding. The new guidance method may make the procedure safer or more precise.
Hear when a new Hepatic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.